AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 93 min read$JNJ

Johnson & Johnson's Icotyde Shows Strong Phase 3 Results for Pla

Johnson & Johnson (JNJ) reported positive phase 3 trial results for Icotyde (icotrokinra) in treating plaque psoriasis, with 72% of patients achieving PASI 90. JNJ offers a 1.95% dividend yield with a 55% payout ratio and a GF Score™ of 83. Despite a 34.1% premium to its GF Value™, the dividend is deemed sustainable. Insider and guru activity shows net selling.

Original reporting
gurufocus.com
Published Oct 9, 2026, 4:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 5:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The Phase 3 data adds a new growth catalyst, potentially boosting earnings outlook and dividend sustainability.

02

Market read

Positive trial results for Icotyde could drive short‑term buying and improve sector sentiment for large pharma.

03

What to watch

Potential regulatory hurdles and competition from other biologics may temper long‑term impact.

Relevance 7/10Novelty 8/10Timing: today

Background

Johnson & Johnson is a diversified healthcare giant with a large dividend and a market cap over $600 B.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson announced positive Phase 3 trial results for its psoriasis drug Icotyde, showing 72% PASI 90 response.

Expected impact

upward pressure as market prices in potential revenue from Icotyde

Evidence & confidence

Phase 3 success is material, new information that can drive near‑term buying interest.

Market effects

Sector

Strengthens outlook for the broader dermatology/auto‑immune drug segment.

Regional

U.S. healthcare stocks may see modest gains on the news.

Global

Highlights continued pipeline strength of large pharma firms worldwide.

Counterpoint

What could challenge this read

High valuation and recent insider selling could limit upside despite trial success.

Key entities

  • company
    Johnson & Johnson

    US‑listed healthcare conglomerate (ticker JNJ).

Read at source← All news

StoryJohnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis

Also covered by

3 outlets

Related articles

OCT 11
$JNJMedAI 9/10

Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years

Johnson & Johnson (JNJ) reported that its oral psoriasis drug, ICOTYDE, maintained skin clearance through 112 weeks in a Phase 3 study, with 89% of genital psoriasis patients and 60% of scalp psoriasis patients achieving complete clearance. The study, presented at a dermatology congress, showed improved outcomes in difficult-to-manage areas, with no new safety concerns identified. JNJ aims to differentiate ICOTYDE in the psoriasis treatment market with its oral delivery.

mychesco.com2 min
OCT 9
$JNJMed

ICONIC-LEAD: Icotrokinra Sustains Psoriasis Skin Clearance at 2 Years

Johnson & Johnson's icotrokinra (Icotyde) showed sustained skin clearance and itch improvement in moderate-to-severe plaque psoriasis patients over 2 years, according to phase 3 ICONIC-LEAD study data. At least 72% of patients achieved PASI 90 and 70% achieved IGA 0/1. The drug is approved in the US, Europe, Japan, and China for adults and adolescents.

hcplive.com2 min
OCT 9
$JNJMed

Johnson & Johnson Announces New Two-Year Results from Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE in Adults and Adolescents with Moderate-To-Severe Plaque Psoriasis

Johnson & Johnson presented two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE® in moderate-to-severe plaque psoriasis. Data showed high skin clearance rates and sustained symptom improvement with no new safety signals. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The study included 684 participants, with 66 adolescents. ICOTYDE is approved in the U.S., Europe, Japan, and China for psoriasis treatment.

marketscreener.com2 min
OCT 9
$BSXMed

Boston sues J&J subsidiary over alleged patent infringement for cardiology device

Boston Scientific sued Johnson & Johnson subsidiary Atraverse Medical, alleging patent infringement by its Hotwire device. Boston claims Atraverse knew its actions infringed Patent '955 and seeks damages and an injunction. J&J acquired Atraverse in 2026. The electrophysiology ablation catheter market is growing at 11.1% CAGR, with J&J's Biosense Webster leading at 43.1% market share in 2025.

finance.yahoo.com2 min
OCT 9
$JNJMedAI 8/10

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

mugglehead.com2 min